Scalable, cGMP‐compatible purification of extracellular vesicles carrying bioactive human heterodimeric IL‐15/lactadherin complexes

Abstract

The development of extracellular vesicles (EV) for therapeutic applications is contingent upon the establishment of reproducible, scalable, and high‐throughput methods for the production and purification of clinical grade EV. Methods including ultracentrifugation (U/C), ultrafiltration, immunoprecipitation, and size‐exclusion chromatography (SEC) have been employed to isolate EV, each facing limitations such as efficiency, particle purity, lengthy processing time, and/or sample volume. We developed a cGMP‐compatible method for the scalable production, concentration, and isolation of EV through a strategy involving bioreactor culture, tangential flow filtration (TFF), and preparative SEC. We applied this purification method for the isolation of engineered EV carrying multiple complexes of a novel human immunostimulatory cytokine‐fusion protein, heterodimeric IL‐15 (hetIL‐15)/lactadherin. HEK293 cells stably expressing the fusion cytokine were cultured in a hollow‐fibre bioreactor. Conditioned medium was collected and EV were isolated comparing three procedures: U/C, SEC, or TFF + SEC. SEC demonstrated comparable particle recovery, size distribution, and hetIL‐15 density as U/C purification. Relative to U/C, SEC preparations achieved a 100‐fold reduction in ferritin concentration, a major protein‐complex contaminant. Comparative proteomics suggested that SEC additionally decreased the abundance of cytoplasmic proteins not associated with EV. Combination of TFF and SEC allowed for bulk processing of large starting volumes, and resulted in bioactive EV, without significant loss in particle yield or changes in size, morphology, and hetIL‐15/lactadherin density. Taken together, the combination of bioreactor culture with TFF + SEC comprises a scalable, efficient method for the production of highly purified, bioactive EV carrying hetIL‐15/lactadherin, which may be useful in targeted cancer immunotherapy approaches.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 38

1. 1.

   Lane RE, Korbie D, Anderson W, et al Analysis of exosome purification methods using a model liposome system and tunable-resistive pulse sensing. Sci Rep. 2015;5: 7639 Epub 2015/ 01/07.

   Not in our library10.1038/srep07639

2. 2.

   Dickens AM, Tovar YRLB, Yoo SW, et al Astrocyte-shed extracellular vesicles regulate the peripheral leukocyte response to inflammatory brain lesions. Sci Signal. 2017;10:eaai7696.

   Not in our library10.1126/scisignal.aai7696

3. 3.
   Malignant extracellular vesicles carrying MMP1 mRNA facilitate peritoneal dissemination in ovarian cancer · 2017

   No notice
4. 4.
   Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells · 2017

   No notice
5. 5.

   Syn NL, Wang L, Chow EK, et al Exosomes in cancer nanomedicine and immunotherapy: prospects and challenges. Trends Biotechnol. 2017;35:665–16.

   Not in our library10.1016/j.tibtech.2017.03.004

6. 6.
   A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer · 2005

   No notice
7. 7.

   Besse B, Charrier M, Lapierre V, et al Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology. 2016;5:e1071008.

   Not in our library10.1080/2162402x.2015.1071008

8. 8.
   Dendritic Cell-Derived Exosomes Promote Natural Killer Cell Activation and Proliferation: A Role for NKG2D Ligands and IL-15Rα · 2009

   No notice
9. 9.

   Bergamaschi C, Rosati M, Jalah R, et al Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity. J Biol Chem. 2008;283:4189–4199.

   Not in our library10.1074/jbc.m705725200

10. 10.

    Van den Bergh J, Willemen Y, Lion E, et al Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity. Oncotarget. 2015;6:44123–44133.

    Not in our library10.18632/oncotarget.6536

11. 11.

    Bergamaschi C, Bear J, Rosati M, et al Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serum. Blood. 2012;120:e1–8.

    Not in our library10.1182/blood-2011-10-384362

12. 12.

    Chertova E, Bergamaschi C, Chertov O, et al Characterization and favorable in vivo properties of heterodimeric soluble IL-15·IL-15Rα cytokine compared to IL-15 monomer. J Biol Chem. 2013;288:18093–18103.

    Not in our library10.1074/jbc.m113.461756

13. 13.

    Bergamaschi C, Kulkarni V, Rosati M, et al Intramuscular delivery of heterodimeric IL-15 DNA in macaques produces systemic levels of bioactive cytokine inducing proliferation of NK and T cells. Gene Ther. 2015;22:76–86.

    Not in our library10.1038/gt.2014.84

14. 14.

    Ng SS, Nagy BA, Jensen SM, et al Heterodimeric IL15 treatment enhances tumor infiltration, persistence, and effector functions of adoptively transferred tumor-specific T cells in the absence of lymphodepletion. Clin Cancer Res. 2017;23:2817–2830.

    Not in our library10.1158/1078-0432.ccr-16-1808

15. 15.

    Watson DC, Bayik D, Srivatsan A, et al Efficient production and enhanced tumor delivery of engineered extracellular vesicles. Biomaterials. 2016;105:195–205.

    Not in our library10.1016/j.biomaterials.2016.07.003

16. 16.

    Alvarez-Erviti L, Seow Y, Yin H, et al Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29: 341–345. Epub 2011/ 03/23.

    Not in our library10.1038/nbt.1807

17. 17.

    Yoshimura A, Kawamata M, Yoshioka Y, et al Generation of a novel transgenic rat model for tracing extracellular vesicles in body fluids. Sci Rep. 2016;6:31172.

    Not in our library10.1038/srep31172

18. 18.

    Delcayre A, Estelles A, Sperinde J, et al Exosome Display technology: applications to the development of new diagnostics and therapeutics. Blood Cells Mol Dis. 2005;35:158–168.

    Not in our library10.1016/j.bcmd.2005.07.003

19. 19.

    Andersen MH, Graversen H, Fedosov SN, et al Functional analyses of two cellular binding domains of bovine lactadherin. Biochemistry. 2000;39:6200–6206.

    Not in our library10.1021/bi992221r

20. 20.

    Matsumoto A, Takahashi Y, Nishikawa M, et al Role of phosphatidylserine-derived negative surface charges in the recognition and uptake of intravenously injected b16bl6-derived exosomes by macrophages. J Pharm Sci. 2017;106: 168–175. Epub 2016/ 09/22.

    Not in our library10.1016/j.xphs.2016.07.022

21. 21.

    Lamparski HG, Metha-Damani A, Yao JY, et al Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods. 2002;270:211–226.

    Not in our library10.1016/s0022-1759(02)00330-7

22. 22.

    Kordelas L, Rebmann V, Ludwig AK, et al MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia. 2014;28:970–973.

    Not in our library10.1038/leu.2014.41

23. 23.

    Jong AY, Wu CH, Li J, et al Large-scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells. J Extracell Vesicles. 2017;6:1294368.

    Not in our library10.1080/20013078.2017.1294368

24. 24.

    Linares R, Tan S, Gounou C, et al High-speed centrifugation induces aggregation of extracellular vesicles. J Extracell Vesicles. 2015;4:29509.

    Not in our library10.3402/jev.v4.29509

25. 25.

    Monguió-Tortajada M, Roura S, Gálvez-Montón C, et al Nanosized UCMSC-derived extracellular vesicles but not conditioned medium exclusively inhibit the inflammatory response of stimulated T cells: implications for nanomedicine. Theranostics. 2017;7:270–284.

    Not in our library10.7150/thno.16154

26. 26.

    Mol EA, Goumans MJ, Doevendans PA, et al Higher functionality of extracellular vesicles isolated using size-exclusion chromatography compared to ultracentrifugation. Nanomed: Nanotechnol, Biol Med. 2017;13:2061–2065.

    Not in our library10.1016/j.nano.2017.03.011

27. 27.

    Blans K, Hansen MS, Sørensen LV, et al Pellet-free isolation of human and bovine milk extracellular vesicles by size-exclusion chromatography. J Extracell Vesicles. 2017;6:1294340.

    Not in our library10.1080/20013078.2017.1294340

28. 28.

    Lobb RJ, Becker M, Wen SW, et al Optimized exosome isolation protocol for cell culture supernatant and human plasma. J Extracell Vesicles. 2015;4:27031.

    Not in our library10.3402/jev.v4.27031

29. 29.

    Heinemann ML, Ilmer M, Silva LP, et al Benchtop isolation and characterization of functional exosomes by sequential filtration. J Chromatogr A. 2014;1371: 125–135. Epub 2014/ 12/03.

    Not in our library10.1016/j.chroma.2014.10.026

30. 30.

    Consortium E-T, Van Deun J, Mestdagh P, et al EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research. Nat Methods. 2017;14:228–232.

    Not in our library10.1038/nmeth.4185

31. 31.

    Lasser C, Eldh M, Lotvall J. Isolation and characterization of RNA-containing exosomes. J Vis Exp. 2012;(59):e3037 Epub 2012/ 01/20.

    Not in our library10.3791/3037

32. 32.

    Haldar S, Bevers LE, Tosha T, et al Moving Iron through ferritin protein nanocages depends on residues throughout each four α-helix bundle subunit. J Biol Chem. 2011;286:25620–25627.

    Not in our library10.1074/jbc.m110.205278

33. 33.

    Mi H, Huang X, Muruganujan A, et al PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements. Nucleic Acids Res. 2017;45:D183–D189.

    Not in our library10.1093/nar/gkw1138

34. 34.

    Xu S, Gavin J, Jiang R, et al Bioreactor productivity and media cost comparison for different intensified cell culture processes. Biotechnol Prog. 2017;33:867–878.

    Not in our library10.1002/btpr.2415

35. 35.

    Engering A, Kuhn L, Fluitsma D, et al Differential post-translational modification of CD63 molecules during maturation of human dendritic cells. Eur J Biochem. 2003;270:2412–2420.

    Not in our library10.1046/j.1432-1033.2003.03609.x

36. 36.

    Patil S, Vhora I, Amrutiya J, et al Role of nanotechnology in delivery of protein and peptide drugs. Curr Pharm Des. 2015;21:4155–4173.

    Not in our library10.2174/1381612821666150901095722

37. 37.

    Kooijmans S, Gitz-Francois J, Vader P, et al PW4.05: recombinant phosphatidylserine-binding proteins for targeting of extracellular vesicles to tumour cells: a plug-and-play. J Extracellular Vesicles. 2016;5:31552.

    Not in our library10.1039/c7nr06966a

38. 38.

    Vang B, Nankervis B, Nguyen K Automated extracellular vesicle production and concentration from bone marrow-derived mesenchymal stem cells. J Extracellular Vesicles. 2016;5:31552.27247029

    Not in our library

Cited by papers we hold 6

• Extracellular vesicle-based drug overview: research landscape, quality control and nonclinical evaluation strategies · 2025
  Corrected
• First‐in‐human clinical trial of allogeneic, platelet‐derived extracellular vesicles as a potential therapeutic for delayed wound healing · 2023
  No notice
• Scalable Production of Extracellular Vesicles and Its Therapeutic Values: A Review · 2022
  No notice
• Mesenchymal stem cells-derived exosomes for drug delivery · 2021
  No notice
• ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance · 2021
  No notice
• Exosome-mediated delivery of inflammation-responsive Il-10 mRNA for controlled atherosclerosis treatment · 2021
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.